{"name":"James A. Tumlin, MD","slug":"james-a-tumlin-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Renin-Angiotensin (RAAS) alone","genericName":"Renin-Angiotensin (RAAS) alone","slug":"renin-angiotensin-raas-alone","indication":"Hypertension","status":"marketed"}]}],"pipeline":[{"name":"Renin-Angiotensin (RAAS) alone","genericName":"Renin-Angiotensin (RAAS) alone","slug":"renin-angiotensin-raas-alone","phase":"marketed","mechanism":"RAAS inhibitors block the renin-angiotensin-aldosterone system to reduce blood pressure and protect organs from hypertension-related damage.","indications":["Hypertension","Heart failure","Chronic kidney disease","Post-myocardial infarction","Diabetic nephropathy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-20","type":"pipeline","source":"The Manila Times","summary":"Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - The Manila Times","headline":"Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOMDdqNWgycWRvWmh1QW4zbjVaTHhXNHcxODRsbDItOUxIVUp5NGJZUDB2T3ozOGszY0stdjBFbWFzcFdTdDNvazE5M3VfbXo2MW9ZMVY4S290SnprVV9DRzljMUlaZWFoZjJRX2s4amdsWXlCR0c4OHBJdE92WU9ReWVMM1lZRjY5WFZvLUJPbW9sZi1EWjJTNw?oc=5","date":"2025-11-13","type":"trial","source":"HCPLive","summary":"Povetacicept Data Validate APRIL/BAFF Inhibition in IgAN and pMN, With James Tumlin, MD - HCPLive","headline":"Povetacicept Data Validate APRIL/BAFF Inhibition in IgAN and pMN, With James Tumlin, MD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNc0U3Qml1WVQ2NFRSSmtzalMwekhRS1BDcHN2T2JjNnB1Q05rT0tPOHlhdDdlcnM0X09EZzZjaDhZcGFQYkdmRXc1bVlZZFZNbThveHUyVW90N1J3c1hGd1k1c2FxbGQ3N0VmdkpLcXpySmN2bWN5YWFPU3hyME5VTVMyd3BIMTdTclEzakJpXzJVcTF6VUdN?oc=5","date":"2025-04-15","type":"pipeline","source":"HCPLive","summary":"Sparsentan and Progression to Kidney Failure in FSGS, with James Tumlin, MD - HCPLive","headline":"Sparsentan and Progression to Kidney Failure in FSGS, with James Tumlin, MD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE5PYndlcDg0Zm1zaVMzbVNFb2NCYjBDc0ItRnlZajhWbEl3ZjNpdDV3Q2hCbkJ1LUREOXdLNU1CSjJxMWJtbW5YOU1PQW9jbGlyUTJ0UGVSZUpkNXU3OHJFXw?oc=5","date":"2017-05-21","type":"pipeline","source":"NEJM","summary":"Angiotensin II for the Treatment of Vasodilatory Shock - NEJM","headline":"Angiotensin II for the Treatment of Vasodilatory Shock","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}